(Reuters) – The European Medicines Agency on Tuesday said it was extending the review of possible suicidal thoughts after use of Novo Nordisk’s drugs Ozempic and Saxenda, to include other diabetes and weight-loss drugs in the same class.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Maju Samuel)
